Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie and Google's Calico strike $1.5bn age-related drug deal

This article was originally published in Scrip

Executive Summary

AbbVie and Google's mysterious life sciences company Calico announced a plan to co-invest up to $1.5bn in a research collaboration to develop new therapies that treat age-related diseases, including neurodegeneration and cancer.

You may also be interested in...



BIO Notebook, Day 1: Janssen, Boehringer And More Talk Deals, Pipeline Progress And Investment

Scrip begins its week at the BIO International Convention with interviews and panel discussions about dealmaking and progressing development pipelines. Among the first day highlights: Janssen's hunt for technology, Boehringer's NASH plans and rising investment in neuroscience.

Amgen Hands Omecamtiv Back To Cytokinetics

While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.

Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer

Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.

Topics

Related Companies

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel